Jazz Pharmaceuticals (JAZZ) Asset Writedowns and Impairment (2014 - 2023)

Jazz Pharmaceuticals' Asset Writedowns and Impairment history runs 6 years deep, the most recent figure standing at $61.0 million for Q4 2023.

• On a quarterly basis, Asset Writedowns and Impairment rose 145.65% year-over-year to $61.0 million in Q4 2023; TTM through Dec 2023 was $61.0 million, a N/A change from a year earlier, with the FY2023 full-year figure at $61.0 million, changed N/A from the prior year.
• Asset Writedowns and Impairment rose to $61.0 million in Q4 2023 per JAZZ's latest filing, from -$133.6 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $136.1 million in Q1 2020 and bottomed at -$133.6 million in Q4 2022.
• The 3-year median for Asset Writedowns and Impairment is $97.3 million (2022), against an average of $49.3 million.
• Biggest YoY gain for Asset Writedowns and Impairment was 145.65% in 2023; the steepest drop was 145.65% in 2023.
• Year by year, Asset Writedowns and Impairment stood at $136.1 million in 2020, then slumped by 198.17% to -$133.6 million in 2022, then soared by 145.65% to $61.0 million in 2023.
• Per Business Quant, the three latest JAZZ Asset Writedowns and Impairment figures stand at $61.0 million (Q4 2023), -$133.6 million (Q4 2022), and $133.6 million (Q3 2022).